NCT01299870.

Methods	Phase II, randomised, double‐blind, cross‐over trial
Participants	Female participants between the ages of 21 and 45 years with a positive diagnosis of catamenial epilepsy
Interventions	Keishibukuryogan versus placebo (added to usual antiepileptic drug treatment) for 12 weeks Follow‐up: up to 36 weeks
Outcomes	Safety (up to 36 weeks) Change in seizure frequency (with a focus on an increase in seizure frequency, up to 36 weeks) Change in progesterone levels (up to 36 weeks)
Notes	Results "submitted" to ClinicalTrials.gov, but not published online or within any journal article known to us. Awaiting assessment if results can be identified.